Product Description
R-107 is the first and only drug to demonstrate a durable reversal of establisheddisease in a validated MCT-induced rodent model of PAH. (Sourced from: https://claritaspharma.com/our-company-our-products-in-development/r-107-for-pah/)
Mechanisms of Action: GUC Activator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Claritas
Company Location:
Company CEO:
Additional Commercial Interests: Salzman Group
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 3
Highest Development Phases
Phase 1: Depressive Disorder
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ACTRN12624001308583 | P1 |
Not yet recruiting |
Depressive Disorder |
None |
|
| ACTRN12622000446763 | P1 |
Not yet recruiting |
Depressive Disorder |
None |
|
| ACTRN12618001135202 | P1 |
Not yet recruiting |
Depressive Disorder |
None |